Selected Publications
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group: Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial American Journal of Respiratory and Critical Care Medicine 205 (5): 529-539,2022.
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators: A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment American Journal of Respiratory and Critical Care Medicine 65 (1): 1295-1305,2021.
Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA: Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation Journal of Cystic Fibrosis 20 (2): 288-294,2021.
Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan D, Kohanski MA, Palmer JN, Adappa ND: Impact of Novel CFTR Modulator on Sinonasal Quality of Life in Adult Patients with Cystic Fibrosis International Forum of Allergy & Rhinology 11 (2): 201-203,2021.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, and Daley CL for the WILLOW Investigators: Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis New England Journal of Medicine 383 (22): 2127-2137,2020.
Krymskaya VP, Courtwright AM, Fleck V, Dorgan D, Kotloff R, McCormack FX, Kreider M: A phase II clinical trial of the Safety of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex Respiratory Medicine 163 : 105898 (ePub),2020.
Hong G, Alby K, Ng SCW, Fleck V, Kubrak C, Rubenstein RC, Dorgan DJ, Kawut SM, Hadjiliadis D: The Presence of Aspergillus fumigatus is Associated with Worse Respiratory Quality of Life in Cystic Fibrosis Journal of Cystic Fibrosis 19 (1): 125-130,2020.
Carey GB, Tebas P, Vinnard C, Kim D, Hadjiliadis D, Hansen-Flaschen J, Dorgan D, Glaser L, Barton G, Hamilton KW: Clinical Outcomes of Clofazimine Use for Rapidly Growing Mycobacterial Infections Open Forum Infectious Diseases 6 (11): 2019.
Ramos KJ, Smith PK, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, and Dunitz JM for the CF Lung Transplant Referral Guidelines Committee: Lung Transplant Referral for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Consensus Guidelines Journal of Cystic Fibrosis 18 (3): 321-333,2019.
David E. Griffith, Gina Eagle, Rachel Thomson, Timothy R. Aksamit, Naoki Hasegawa, Kozo Morimoto, Doreen J. Addrizzo-Harris, Anne E. O’Donnell, Theodore K. Marras, Patrick A. Flume, Michael R. Loebinger, Lucy Morgan, Luigi R. Codecasa, Adam T. Hill, Stephen J. Ruoss, Jae-Joon Yim, Felix C. Ringshausen, Stephen K. Field, Julie V. Philley, Richard J. Wallace Jr., Jakko van Ingen, Chris Coulter, James Nezamis, and Kevin L. Winthrop; for the CONVERT Study Group: Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study American Journal of Respiratory and Critical Care Medicine 198 (12): 1559-1569,2018.
Academic Contact Information
Harron Lung Center
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-662-3202
Patient appointments: 800-789-7366